{"protocolSection": {"identificationModule": {"nctId": "NCT00789321", "orgStudyIdInfo": {"id": "0000-106"}, "secondaryIdInfos": [{"id": "2008_580"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate Methodologies for Measuring Swelling of the Leg and Ankle (MK-0000-106)(COMPLETED)", "officialTitle": "A Randomized Clinical Trial to Evaluate the Effects of Multiple Doses of Amlodipine 10 mg on Pedal Edema Measurements in Middle-Aged and Elderly Healthy Subjects and Patient With Hypertension"}, "statusModule": {"statusVerifiedDate": "2015-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-07"}, "primaryCompletionDateStruct": {"date": "2009-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-11-10", "studyFirstSubmitQcDate": "2008-11-10", "studyFirstPostDateStruct": {"date": "2008-11-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-04-30", "resultsFirstSubmitQcDate": "2010-06-08", "resultsFirstPostDateStruct": {"date": "2010-07-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-08-10", "lastUpdatePostDateStruct": {"date": "2015-08-11", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study will evaluate methodologies for measuring pedal edema associated with calcium channel blockers in middle-aged and elderly subjects and patients with hypertension."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 47, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "amlodipine", "interventionNames": ["Drug: Comparator: amlodipine besylate"]}, {"label": "2", "type": "PLACEBO_COMPARATOR", "description": "Placebo to amlodipine", "interventionNames": ["Drug: Comparator: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Comparator: amlodipine besylate", "description": "Two 5 mg tablets amlodipine daily for 6 weeks.", "armGroupLabels": ["1"]}, {"type": "DRUG", "name": "Comparator: Placebo", "description": "Two 5 mg tablets placebo to amlodipine daily for 6 weeks", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Segmental Bioimpedance Measurements at 10 Kilohertz (KHz) at Week 2", "description": "Segmental biomimpedance was measured using a multifrequency analyzer (ImpediMed SFB7). The device was used to measure impedance (measured in Ohms) of a small current traveling between leads placed at the ankle and knee. Least Squares Mean Difference from Baseline in impedance is the primary endpoint.", "timeFrame": "Baseline and 2 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Foot Volume by Water Displacement (Weight of Water Displaced) at Week 2", "description": "Least Squares Mean Difference from Baseline", "timeFrame": "Baseline and 2 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient does not have hypertension or has Stage I or II hypertension and is taking \\< 3 anti-hypertension medications\n* Patient is willing to discontinue all anti-hypertensive medications during study\n* Patient is willing to refrain from drinking alcohol for 24 hours prior to each study visit and is willing to limit intake at other times during the study to 2 drinks per day\n* Patient agrees to avoid caffeine for 24 hours prior to each study visit. At other times during study, daily caffeine intake should not exceed 4 cups of coffee (or equivalent)\n* Patient will avoid strenuous physical activity during study\n* Patient is a nonsmoker or has not smoked for the last 3 months\n\nExclusion Criteria:\n\n* Patient has metal implants in the leg or artificial limbs\n* Patient has had a lower limb amputation, malformation, alterations in leg muscles, or a history of musculoskeletal disease\n* Patient has used oral contraceptive pills or hormone replacement therapy within 3 months of screening\n* Patient has a history of stroke or seizures\n* Patient has a history of cancer, except that which was treated at least 10 years prior to screening and shows no evidence of recurrence", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "50 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "22385927", "type": "DERIVED", "citation": "Schoeller DA, Alon A, Manekas D, Mixson LA, Lasseter KC, Noonan GP, Bolognese JA, Heymsfield SB, Beals CR, Nunes I. Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study. Clin Ther. 2012 Mar;34(3):580-92. doi: 10.1016/j.clinthera.2012.01.018. Epub 2012 Mar 3."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants taking anti-hypertensive medications at screening were required to washout of this therapy before randomization and remain off the therapy during the study. Participants were eligible if systolic blood pressure (BP) was \u2265120 to \\<180 mm Hg and diastolic BP was \u226580 to \\<110 mm Hg at screening (or after 2-4 weeks of washout, if applicable)", "recruitmentDetails": "Participants were recruited across 3 Phase I clinical research units in the US. Participants participated from July 2008 to March 2009.", "groups": [{"id": "FG000", "title": "Amlodipine 10 Milligrams", "description": "Participants who were randomized to treatment with amlodipine 10 mg once daily for 6 weeks"}, {"id": "FG001", "title": "Placebo", "description": "Participants who were randomized to treatment with placebo once daily for 6 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "23"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "22"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Amlodipine 10 Milligrams", "description": "Participants who were randomized to treatment with amlodipine 10 mg once daily for 6 weeks"}, {"id": "BG001", "title": "Placebo", "description": "Participants who were randomized to treatment with placebo once daily for 6 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "47"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.4", "spread": "5.6"}, {"groupId": "BG001", "value": "59.6", "spread": "6.2"}, {"groupId": "BG002", "value": "59.0", "spread": "5.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "24"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "23"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28.2", "spread": "2.9"}, {"groupId": "BG001", "value": "29.0", "spread": "2.7"}, {"groupId": "BG002", "value": "28.6", "spread": "2.8"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Segmental Bioimpedance Measurements at 10 Kilohertz (KHz) at Week 2", "description": "Segmental biomimpedance was measured using a multifrequency analyzer (ImpediMed SFB7). The device was used to measure impedance (measured in Ohms) of a small current traveling between leads placed at the ankle and knee. Least Squares Mean Difference from Baseline in impedance is the primary endpoint.", "populationDescription": "All patients treated with segmental bioimpedance measurements at baseline and 2 weeks - one patient in the placebo group was not included (dropped out of study due to viral infection prior to Week 2).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ohms", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Amlodipine 10 Milligrams", "description": "Participants who were randomized to treatment with amlodipine 10 mg once daily for 6 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Participants who were randomized to treatment with placebo once daily for 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.9", "spread": "20.7"}, {"groupId": "OG001", "value": "3.8", "spread": "17.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Change from baseline in systolic blood pressure included as covariate", "paramType": "Least Squares Mean", "paramValue": "-11.7", "ciPctValue": "90", "ciLowerLimit": "-18.1", "ciUpperLimit": "-5.4"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Foot Volume by Water Displacement (Weight of Water Displaced) at Week 2", "description": "Least Squares Mean Difference from Baseline", "populationDescription": "All patients treated with water displacement measurements at baseline and 2 weeks - one patient in the placebo group was not included (dropped out of study due to viral infection prior to Week 2) - two patients in the amlodipine group were excluded due to technical/procedural errors.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Grams", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Amlodipine 10 Milligrams", "description": "Participants who were randomized to treatment with amlodipine 10 mg once daily for 6 weeks"}, {"id": "OG001", "title": "Placebo", "description": "Participants who were randomized to treatment with placebo once daily for 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "44.8", "spread": "64.8"}, {"groupId": "OG001", "value": "5.8", "spread": "53.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Change from baseline in systolic blood pressure included as covariate", "paramType": "Least Squares Mean", "paramValue": "39.0", "ciPctValue": "95", "ciLowerLimit": "17.9", "ciUpperLimit": "60.1"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Amlodipine 10 Milligrams", "description": "Participants who were randomized to treatment with amlodipine 10 mg once daily for 6 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 17, "otherNumAtRisk": 24}, {"id": "EG001", "title": "Placebo", "description": "Participants who were randomized to treatment with placebo once daily for 6 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 16, "otherNumAtRisk": 23}], "otherEvents": [{"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Myodesopsia", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Dry Mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}]}, {"term": "Feeling Hot", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Inflammation", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}]}, {"term": "Oedema Peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 23}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Viral Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}]}, {"term": "Accidental Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 23}]}, {"term": "Arthropod Bite", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Muscle Spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}]}, {"term": "Pain In Extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}]}, {"term": "Tension Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 23}]}, {"term": "Euphoric Mood", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Polyuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Rhinitis Allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Hyperhidrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "clinicaltrialsdisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M7657", "name": "Edema", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Valproic Acid", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}